Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients

Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer

(2018) Jie Cheng et al.   BREAST CANCER RESEARCH AND TREATMENT

Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients

(2018) S. Valpione et al.   EUROPEAN JOURNAL OF CANCER

Liquid biopsy in colon cancer: comparison of different circulating DNA extraction systems following absolute quantification of KRAS mutations using Intplex allele-specific PCR

(2017) Vera Kloten et al.   Oncotarget

A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials

(2016) Emmanuelle Kempf et al.   PLoS One

Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials

(2016) J. Andrew Livingston et al.   Oncotarget

Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms

(2016) Maria Schwaederle et al.   JAMA Oncology

Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients

(2016) Steffen Dietz et al.   PLoS One

Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification

(2014) Alison S. Devonshire et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin

(2012) A Ploquin et al.   BRITISH JOURNAL OF CANCER

Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience

(2012) J. Wheler et al.   CLINICAL CANCER RESEARCH

Life-expectancy of patients enrolled in phase 1 clinical trials: A systematic review of published prognostic models

(2012) Anne Ploquin et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center

(2011) Ignacio Garrido-Laguna et al.   CANCER

Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

(2011) D. Olmos et al.   CLINICAL CANCER RESEARCH

Validation of the Royal Marsden Hospital Prognostic Index in Advanced Esophagogastric Cancer Using Individual Patient Data From the REAL 2 Study

(2009) Ian Chau et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials

(2009) Hendrik-Tobias Arkenau et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience

(2008) H-T Arkenau et al.   BRITISH JOURNAL OF CANCER